Cargando…

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera

We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled in the ECLAP study, 82 and 84 developed arterial and venous thrombosis, respectively. Absolute counts of total leukocy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carobbio, Alessandra, Vannucchi, Alessandro Maria, De Stefano, Valerio, Masciulli, Arianna, Guglielmelli, Paola, Loscocco, Giuseppe Gaetano, Ramundo, Francesco, Rossi, Elena, Kanthi, Yogendra, Tefferi, Ayalew, Barbui, Tiziano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831521/ https://www.ncbi.nlm.nih.gov/pubmed/35145055 http://dx.doi.org/10.1038/s41408-022-00625-5

Ejemplares similares

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera
por: Barbui, Tiziano, et al.
Publicado: (2018)

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Polycythemia vera treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
por: Tefferi, Ayalew, et al.
Publicado: (2021)

Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis
por: Ferrari, Alberto, et al.
Publicado: (2019)

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data
por: Ghirardi, Arianna, et al.
Publicado: (2018)

An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
por: Barbui, T, et al.
Publicado: (2015)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera
por: Marchioli, Roberto, et al.
Publicado: (2011)

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
por: Tefferi, A, et al.
Publicado: (2013)

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
por: Cerquozzi, S., et al.
Publicado: (2017)

PB2202: NOVEL PREDICTORS FOR VENOUS AND ARTERIAL THROMBOSIS IN POLYCYTHEMIA VERA
por: Ivanović, Jelena, et al.
Publicado: (2023)

Site‐specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival
por: Gangat, Naseema, et al.
Publicado: (2022)

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
por: Pardanani, A, et al.
Publicado: (2015)

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis
por: Carobbio, Alessandra, et al.
Publicado: (2020)

Partial Status Epilepticus in Cerebral Venous Sinus Thrombosis, Initial Manifestation of Polycythemia Vera
por: Eliaçik, Sinan, et al.
Publicado: (2019)

Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera
por: Martins De Oliveira Filho, Cilomar, et al.
Publicado: (2022)

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
por: De Stefano, Valerio, et al.
Publicado: (2018)

Essential thrombocythemia treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Mutations and thrombosis in essential thrombocythemia
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Pulmonary vein thrombosis in a patient with polycythemia vera
por: Bhardwaj, Bhaskar, et al.
Publicado: (2016)

Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
por: Barbui, Tiziano, et al.
Publicado: (2022)

RBC distribution width predicts thrombosis risk in polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

A Case Report of Cerebral Venous Thrombosis in Polycythemia Vera Presenting with Intracranial and Spinal Subdural Hematoma
por: Sirin, Nermin Görkem, et al.
Publicado: (2010)

Cerebellar venous thrombosis mimicking a cerebellar tumor due to polycythemia vera: a case report
por: Wen, Hongfeng, et al.
Publicado: (2021)

Cerebral venous sinus thrombosis in polycythemia vera patients with JAK2V617F mutation
por: Shen, Hui-Xin, et al.
Publicado: (2021)

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
por: Barbui, Tiziano, et al.
Publicado: (2018)

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
por: Barraco, Daniela, et al.
Publicado: (2018)

A Case of Transition of Polycythemia Vera to Chronic Neutrophilic Leukemia
por: Lee, Seung Soon, et al.
Publicado: (2004)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

Diagnosis and Management of Cerebral Venous Thrombosis Due to Polycythemia Vera and Genetic Thrombophilia: Case Report and Literature Review
por: Jianu, Dragos Catalin, et al.
Publicado: (2023)

Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera
por: Nguyen, Eliane, et al.
Publicado: (2021)

Management of polycythemia vera: A survey of treatment patterns in Italy
por: Palumbo, Giuseppe Alberto, et al.
Publicado: (2022)

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
por: Tefferi, A, et al.
Publicado: (2010)

The new WHO classification for essential thrombocythemia calls for revision of available evidences
por: Barbui, Tiziano, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_odgsco1ce20nrp0tn67g2205uv